奈莫单抗用于治疗结节性痒疹和特应性皮炎。

Q1 Medicine

Skin therapy letter Pub Date : 2025-05-01

Mohamad R Taha, Stephen K Tyring

{"title":"奈莫单抗用于治疗结节性痒疹和特应性皮炎。","authors":"Mohamad R Taha, Stephen K Tyring","doi":"","DOIUrl":null,"url":null,"abstract":"Prurigo nodularis and atopic dermatitis are chronic, inflammatory skin conditions characterized by significant pruritus that disrupts daily life. They also involve dysfunction of the T-helper 2 immune response, leading to the over secretion of interleukin-31 (IL-13) in the dermis and serum. Nemolizumab is a new IL-31 receptor antagonist that has shown high efficacy in the treatment of prurigo nodularis (PN) and atopic dermatitis (AD) in multiple phase 3 trials, with a good safety profile. A brief overview of PN and AD including highlights of the findings from three trials of nemolizumab in treating these disorders will be presented herein.","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 3","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis.\",\"authors\":\"Mohamad R Taha, Stephen K Tyring\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Prurigo nodularis and atopic dermatitis are chronic, inflammatory skin conditions characterized by significant pruritus that disrupts daily life. They also involve dysfunction of the T-helper 2 immune response, leading to the over secretion of interleukin-31 (IL-13) in the dermis and serum. Nemolizumab is a new IL-31 receptor antagonist that has shown high efficacy in the treatment of prurigo nodularis (PN) and atopic dermatitis (AD) in multiple phase 3 trials, with a good safety profile. A brief overview of PN and AD including highlights of the findings from three trials of nemolizumab in treating these disorders will be presented herein.\",\"PeriodicalId\":21829,\"journal\":{\"name\":\"Skin therapy letter\",\"volume\":\"30 3\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin therapy letter\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin therapy letter","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

结节性痒疹和特应性皮炎是一种慢性炎症性皮肤病，其特征是明显的瘙痒，扰乱了日常生活。它们还涉及t -辅助性2免疫反应的功能障碍，导致真皮和血清中白细胞介素-31 （IL-13）的过度分泌。Nemolizumab是一种新的IL-31受体拮抗剂，在多个3期试验中显示出治疗结节性痒疹（PN）和特应性皮炎（AD）的高效率，具有良好的安全性。本文将简要概述PN和AD，包括nemolizumab治疗这些疾病的三个试验的重点结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis.

Prurigo nodularis and atopic dermatitis are chronic, inflammatory skin conditions characterized by significant pruritus that disrupts daily life. They also involve dysfunction of the T-helper 2 immune response, leading to the over secretion of interleukin-31 (IL-13) in the dermis and serum. Nemolizumab is a new IL-31 receptor antagonist that has shown high efficacy in the treatment of prurigo nodularis (PN) and atopic dermatitis (AD) in multiple phase 3 trials, with a good safety profile. A brief overview of PN and AD including highlights of the findings from three trials of nemolizumab in treating these disorders will be presented herein.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Skin therapy letter Medicine-Medicine (all)

CiteScore

2.80

自引率

0.00%

发文量

期刊介绍： The premier international journal on the latest advances, techniques and practice in conservation and restoration from around the world.